VisCardia is commercializing Synchronized Diaphragmatic Stimulation™ (SDS® therapy), a proprietary implantable medical device designed to improve cardiac function in patients with heart failure and reduced ejection fraction. This minimally invasive therapy addresses the inadequacy of pharmacological treatments and the need for complex surgical interventions, offering a viable alternative for over 10 million affected patients in the U.S. and Europe.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure affects millions, leading to frequent hospitalizations, reduced quality of life, and significant healthcare costs. Current treatment options are often inadequate, leaving many patients with limited alternatives beyond complex surgical procedures.
Solution
VisCardia is developing Synchronized Diaphragmatic Stimulation (SDS) therapy, a minimally invasive, implantable medical device designed to improve cardiac function in heart failure patients with reduced ejection fraction and preserved ventricular synchrony. SDS therapy aims to address the limitations of pharmacological treatments and the risks associated with major surgeries by offering a viable alternative. The device works by synchronizing diaphragmatic function to improve ventricular function. Clinical studies in Europe have been completed, with results presented at major cardiology scientific meetings.
Target Audience
The primary target audience includes heart failure patients with reduced ejection fraction and preserved ventricular synchrony for whom drug treatments are insufficient, as well as cardiologists and hospitals specializing in heart failure treatment.
Features
- Minimally invasive implantation procedure
- Synchronized Diaphragmatic Stimulation (SDS) technology
- Designed for patients with heart failure and reduced ejection fraction
- Aims to improve cardiac function
- Intended for patients where drugs are inadequate